Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit
By Ben Glickman
Biofrontera is being sued by Sun Pharmaceutical, which alleges the company improperly promoted its Ameluz product.
The Woburn, Mass.-based dermatology-focused biopharmaceutical company said in a Tuesday regulatory filing it had been served the complaint, which was filed by Sun and connected companies on Sept. 13.
Biofrontera denies the claims and "intends to defend these matters vigorously."
The lawsuit alleges Biofrontera committed breach of contract and unfair trade practices and violated the Lanham Act, a trademark law.
"All claims stem from allegations that Biofrontera has promoted its Ameluz product in a manner that is inconsistent with its approved FDA labeling," Biofrontera said in the filing.
The case will be heard in the U.S. District Court for the District of New Jersey.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 03, 2023 18:28 ET (22:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks